Boiron SA (BOI) AI Stock Analysis

• Market Cap: €526.43M
• Dividend Yield: 3.95%
• Average Volume (3M): 4.19K
• Price to Earnings (P/E): 26.9
• Beta (1Y): 0.26
• Revenue Growth: 4.80%
• EPS Growth: -18.25%
• Country: FR
• Employees: 2,469
• Sector: General
• Sector Strength: N/A
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.65
• Shares Outstanding: 17,545,408
• 10 Day Avg. Volume: 1,557
• 30 Day Avg. Volume: 4,187
• PEG Ratio: -0.60
• Price to Book (P/B): 1.23
• Price to Sales (P/S): 0.95
• P/FCF Ratio: 13.78
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 69 Neutral
• Price Target: €30.00 ▼(-1.32% Downside)

Boiron SA's overall stock score is driven by strong technical momentum and a stable financial position, despite challenges in revenue growth and profitability. The valuation suggests potential overvaluation, but the dividend yield offers some appeal.

Positive Factors

Strong Brand Reputation

A strong brand reputation and loyal customer base support repeat sales and market penetration, providing a durable competitive advantage in the homeopathic medicine market.

Low Leverage

Low leverage enhances financial stability and reduces risk, allowing Boiron to navigate economic fluctuations and invest in growth opportunities without significant debt burden.

Cash Generation Ability

Strong cash generation supports operational flexibility and investment capacity, ensuring Boiron can sustain its business operations and pursue strategic initiatives.

Negative Factors

Declining Revenue

Declining revenue indicates challenges in market demand or competitive pressures, potentially impacting long-term growth prospects and market position.

Profit Margin Decline

A decline in profit margins suggests reduced operational efficiency and profitability, which could hinder Boiron's ability to reinvest in its business and maintain competitive edge.

Declining Cash Flow

Declining cash flow may limit Boiron's ability to fund operations and growth initiatives, potentially affecting its financial health and strategic flexibility over time.

Boiron SA Business Overview & Revenue Model

Company Description

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders. The company's homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders. In addition, it provides dietary supplement; Dermoplasmine stick, baume, and mousse to treat dry lips and skin; Mag' Nuit, a formula to fall asleep; Arnitrosium for joint pain; Castor Equi Boiron ointment for treatment of cracked skin; and Storinyl, a syrup to treat colds. Further, it offers herbal medicines, such as Canephron to increase the amount of urine and to improve urinary elimination; moisturizing baby milk; and medical devices, including a range of COVID self-tests and rapid antigenic tests. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.

How the Company Makes Money

Boiron generates revenue primarily through the sale of its homeopathic products, which are distributed to pharmacies, health food stores, and healthcare practitioners. The company operates in various segments, including over-the-counter (OTC) homeopathic medicines and prescription homeopathic products. Key revenue streams include direct sales to consumers, wholesale distribution to retailers, and partnerships with healthcare providers that endorse or recommend its products. Boiron also benefits from brand loyalty and recognition in the homeopathy sector, which helps maintain a steady customer base. Additionally, the company's investment in research and development allows it to innovate and expand its product offerings, contributing to its overall financial performance.

Boiron SA Financial Statement Overview

Summary

Boiron SA exhibits strong balance sheet stability with low leverage, but faces challenges in revenue growth and maintaining profit margins. Cash flow generation is relatively strong, though declining trends need attention.

Income Statement

Boiron SA's income statement shows a decline in total revenue from 2022 to 2024, dropping from €534.2M to €487.6M. The gross profit margin has remained relatively stable, while the net profit margin shows a significant decrease due to declining net income. The company has maintained positive EBIT and EBITDA margins, though both have decreased over the past few years, indicating a reduction in operational efficiency. Overall, the company is facing challenges in maintaining its top-line growth and profitability.

Balance Sheet

The balance sheet of Boiron SA indicates a strong equity position with a debt-to-equity ratio that is very low, showcasing financial stability and low leverage risk. The equity ratio is robust, reflecting good asset management and financial health. However, the declining trend in stockholders' equity and total assets since 2022 suggests potential challenges in asset growth and equity retention.

Cash Flow

Boiron SA's cash flow statement reveals a slight decline in free cash flow over recent years, with a noticeable decrease in both operating cash flow and capital expenditures. The free cash flow to net income ratio remains healthy, indicating strong cash generation relative to profit. However, declining trends in free cash flow growth rate highlight potential concerns in sustaining cash flow levels in the future.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	504.86M	487.56M	493.25M	534.24M	455.20M	513.58M
Gross Profit	372.12M	358.76M	358.08M	379.73M	327.62M	394.74M
EBITDA	56.24M	45.46M	73.67M	91.33M	78.75M	68.91M
Net Income	19.37M	11.34M	35.83M	44.67M	28.56M	26.21M
Balance Sheet
Total Assets	561.59M	576.33M	590.20M	789.49M	770.70M	781.82M
Cash, Cash Equivalents and Short-Term Investments	62.45M	64.71M	74.04M	250.94M	234.50M	234.69M
Total Debt	18.10M	14.97M	13.70M	22.17M	12.61M	12.43M
Total Liabilities	192.47M	198.15M	198.70M	232.15M	238.93M	272.65M
Stockholders Equity	369.10M	378.14M	393.66M	557.62M	531.74M	509.14M
Cash Flow
Free Cash Flow	47.88M	33.77M	27.47M	41.51M	13.46M	47.98M
Operating Cash Flow	55.80M	42.17M	45.49M	60.10M	33.88M	68.68M
Investing Cash Flow	-16.28M	-18.36M	-22.93M	-15.28M	-11.92M	-19.34M
Financing Cash Flow	-26.69M	-27.85M	-198.41M	-28.99M	-22.00M	-21.52M

Boiron SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 30.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BOI, the sentiment is Positive. The current price of 30.4 is above the 20-day moving average (MA) of 30.05, above the 50-day MA of 28.84, and above the 200-day MA of 24.91, indicating a neutral trend. The MACD of 0.30 indicates Positive momentum. The RSI at 53.72 is Neutral, neither overbought nor oversold. The STOCH value of 72.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:BOI.

Boiron SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VETO	72 Outperform	€1.03B	17.08	10.80%	1.06%	-0.95%	27.67%
BOI	69 Neutral	€526.43M	26.94	5.22%	3.95%	4.80%	-18.25%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
ABVX	53 Neutral	€7.77B	-35.42	―	―	―	18.52%
IVA	47 Neutral	€785.83M	-1.09	―	―	-12.84%	-81.94%
MEDCL	46 Neutral	€849.55M	-41.94	―	―	166.31%	43.80%
AB	40 Neutral	€97.95M	-9.91	―	―	-5.08%	-88.04%